Background Good glycaemic control during pregnancy is key to reduce maternal and foetal complications. Insulin degludec, an ultralong acting analogue with a "peakless" and stable pharmacokinetic profile, has the potential advantage of reducing hypoglycaemia and glucose variability compared to other basal insulins. Therefore, degludec could be a reasonable therapeutic option for pregnant women with type 1 diabetes (T1D). However, degludec is not licensed for use during pregnancy owing to the lack of safety data.
Introduction
Good glycaemic control during pregnancy is key to reduce maternal and foetal complications [1, 2] . According to the American Diabetes Association (ADA), target blood glucose levels during pregnancy are equal or below 95 mg/ dl (mmol/l) in fasting conditions, and equal or below 140 or 120 mg/dl (mmol/l) 1 or 2 h after a meal, respectively [3] . However, tight glycaemic control increases the risk of hypoglycaemia and the fear of hypoglycaemia is a major factor limiting the achievement of glycaemic targets [4] . Insulin analogues may improve glycaemic control mainly with a reduction of hypoglycaemia. Ultrarapid analogues have a more rapid onset and a shorter duration of action compared with human insulin, allowing a better control of post-prandial hyperglycaemia [2] and a lower rate of late hypoglycaemia [5] . Long-acting analogues, compared to NPH insulin, have an almost peakless profile and a reduced risk of nocturnal hypoglycaemia [6] . The use of insulin analogues during pregnancy was initially discouraged because there was no safety information, and human insulin was thus preferred. Over the time, accumulating case reports and case series have provided a sufficient amount of information on the safety of insulin aspart and lispro in pregnancy [7] [8] [9] . Moreover, in a large randomized controlled trial, the use of long-acting insulin analogue detemir was found to be similar to NPH in terms of efficacy and safety [10, 11] . As for insulin glargine, most of the studies are small and retrospective. A meta-analysis of eight studies comparing the use of insulin glargine with the use of insulin NPH showed no significant differences in efficacy and in maternal or foetal outcomes [12] .
Insulin degludec, an ultralong-acting analogue, can further reduce the risk of hypoglycaemia, compared to glargine, thanks to a flatter and less variable pharmacokinetic profile [13] . Therefore, degludec appears a reasonable therapeutic option for pregnant women with type 1 diabetes (T1D) who seek to optimize glycaemic control [14] . Nevertheless, since there are no data on pregnancy outcomes in patients who received degludec during conception and/or the rest of pregnancy, degludec is not licensed for use during pregnancy. Thus, women taking degludec should switch to another basal insulin in case of planned pregnancy or as soon as possible after pregnancy diagnosis. The ongoing EXPECT trial (NCT03377699) will establish the efficacy and safety of insulin degludec versus detemir in pregnancy, but results are expected by 2021. Meanwhile, retrospective data or case reports can contribute with important information on this clinically relevant topic.
We herein report three cases of unplanned pregnancy in women with poorly controlled type 1 diabetes treated with insulin degludec during the first trimester or the whole pregnancy.
Case 1
A 37-year-old Caucasian woman with a history of T1D since 12 years became pregnant for the first time while she was being treated with multiple daily insulin injections: aspart 2 IU at breakfast, 6 IU at lunch and dinner, and degludec 14 IU at bedtime. Degludec had been started 9 months earlier because of wide glycaemic variability and poor glycaemic control under a basal-bolus regimen with insulin aspart and detemir. After switching from twice-daily detemir to degludec, she reported improved glycaemic control and better treatment satisfaction. The patient had a history of papillary thyroid carcinoma and she was on treatment with levothyroxine.
The patient visited our outpatient clinic at 5 weeks of unplanned pregnancy. Her body weight was 57 kg, and latest HbA1c 69 mmol/mol (8.5%). She had a moderate non-proliferative diabetic retinopathy, normoalbuminuria (7 mg/g of creatinine), and no sign of macrovascular complications. We informed the patient about maternal and foetal complications due to hyper-and hypoglycaemia in pregnancy. We warned her that degludec was not licensed for use during pregnancy because studies on its foetal and maternal safety were unavailable, and we proposed a switch to glargine. The patient decided to stay on degludec, as she was afraid that her glucose control would otherwise have worsened and threatened the foetus. The patient gave her written informed consent to continue insulin degludec during pregnancy. Glycaemic targets were adjusted as recommended by the ADA and insulin doses changed accordingly. The dose of levothyroxine was increased.
During pregnancy, glycaemic control progressively improved, reaching an HbA1c value of 55 mmol/mol (7.2%) in the first trimester, 51 mmol/mol (6.8%) at the beginning of the second trimester, and 50 mmol/mol (6.7%) at the beginning of the third trimester. Insulin need increased from 25 IU/day (aspart 11 IU and degludec 14 IU) before pregnancy (0.46 IU/kg) to 42 IU (aspart 27 IU and degludec 15 IU)) at the 27th week of gestation, when her body weight was 63 kg (0.66 IU/kg). No severe or moderate hypoglycaemic episodes occurred during pregnancy and no progression of retinopathy was observed upon ophthalmologic examination. Blood pressure was always normal. Ultrasound examinations of the foetus showed normal morphology and the estimated foetus weight was always adequate for gestational age.
At the 22nd week of gestation, the patient was admitted to the emergency department for slight vaginal bleeding. Physical examination revealed an extensive bleeding ectropion. At the 28th week of gestation, the patient was admitted to the obstetric clinic for threatened preterm birth and suspected preterm premature rupture of membranes. She received infusion of antibiotic, corticosteroids and atosiban, an oxytocin antagonist, to delay delivery.
The pregnancy ended at the 29th week of gestation with a caesarean section for abnormal foetal cardiotocography. The patient gave birth to a premature but healthy girl with no malformations. The newborn weighed 1730 g, was 41 cm long, and the American Pediatric Gross Assessment Record (APGAR) indexes were 7/10 and 8/10 at 1 and 5 min, respectively. The baby was admitted to neonatal intensive care unit because of increased bilirubin concentrations and episodes of apnoea. Echocardiographic and ultrasonic investigations of the encephalon after birth were normal and she was then discharged. At the last follow-up available (May 2018), the baby was developing in a completely normal way.
Case 2
A 26-year-old Caucasian woman with T1D diagnosed at the age of 7 years was admitted to our division of metabolic diseases for poor glycaemic control at 5 weeks of unplanned pregnancy. Her pre-pregnancy HbA1c was 79 mmol/mol (9.4%). She had no evidence of diabetic complications. She was on treatment with insulin lispro 4 IU at each meal and insulin degludec 20 IU at bedtime. Degludec had been started 7 months earlier because of wide glycaemic variability, poor glycaemic control, and frequent nocturnal hypoglycaemias during a basal-bolus regimen with insulin glargine. At admission, HbA1c was 57 mmol/mol (7.4%), insulin degludec was discontinued and glargine was started and titrated to achieve ADA glycaemic targets. The patient's echocardiography revealed a mild stenosis of the mitral bioprosthesis and an antiplatelet agent was started. The patient was discharged with a daily bolus insulin need of 9 IU and basal insulin need of 16 IU. At 21 weeks of gestation, she was switched to continuous subcutaneous insulin infusion (CSII) and glycaemic control progressively improved: HbA1c declined to 56 mmol/mol (7.3%) and 45 mmol/mol (6.3%) at 15 and 21 weeks of gestation, respectively.
Total gestational weight gain was approximately 8 kg and no maternal cardiac complications occurred. Repeated ultrasound scans showed normal foetal growth and cardiac morphology. At 35 weeks of gestation, the patient gave birth to a normal boy by planned caesarean section. The baby was healthy, weighed 2900 g and had APGAR scores of 10/10 and 10/10 at 1 and 5 min, respectively.
Case 3
A 22-year-old Caucasian woman with T1D since the age of 9 years was referred to our clinic, at 7 weeks of unplanned pregnancy. At the time of conception, her body weight was 59 kg, HbA1c was 77 mmol/mol (9.2%) under treatment with insulin aspart (3 IU at breakfast, 11 IU at lunch, 6 IU at dinner) and degludec 28 IU at bedtime. Micro-and macrovascular complications were absent. We warned her that degludec was not licensed for use during pregnancy and degludec was thus replaced with insulin glargine, starting equidose. During pregnancy, the patient's glycaemic control remained poor. Her HbA1c at the second and third trimester was 59 mmol/mol (7.6%) and 66 mmol/mol (8.2%), respectively. At 30 weeks of gestation, the patient was admitted to the obstetric Clinic for poor glycaemic control. Insulin doses were progressively increased to 94 IU (insulin aspart 15 IU at breakfast, 25 IU at lunch, 20 IU at dinner, and insulin glargine split into two doses: 7 IU at 8 a.m. and 27 IU at 8 p.m.). During hospitalization, glycaemic control progressively improved. Ultrasound monitoring of foetal growth was always normal. No development of retinopathy or nephropathy occurred. Total gestational weight gain was approximately 14 kg.
The pregnancy ended at the 37th week of gestation with a caesarean section for abnormal foetal cardiotocography. The patient gave birth to a healthy boy with no malformations. The newborn weighed 3930 g, was 50 cm long and had APGAR scores of 9/10 and 10/10 at 1 and 5 min, respectively.
Discussion
Insulin degludec is not recommended during pregnancy because there is no available study on materno-foetal outcomes. No embryo toxicity or teratogenicity with insulin degludec has been shown in animal experiments: pregnancy outcome or foetal loss did not differ between diabetic rats or rabbit receiving insulin degludec compared to human insulin, even with doses up to five-ten times the human exposure (https ://www.acces sdata .fda.gov/drugs atfda _docs/ label /2015/20331 4lbl.pdf).
The ongoing "Research Study Comparing Insulin Degludec to Insulin Detemir, Together with Insulin Aspart, in Pregnant Women with Type 1 Diabetes" (EXPECT, NCT03377699) will shed light on the efficacy and maternofoetal safety of insulin degludec.
To find other similar reports in the literature, we searched PubMed with the following terms "degludec" AND ("pregnancy" OR "pregnant"). We excluded articles not reporting novel information. Two reports of women with T1D who continued pre-conception degludec treatment during early pregnancy have been published in 2017 [15] . In both cases, pregnant women were switched from degludec to another basal insulin at the first visit after pregnancy diagnosis, one at 12 weeks and the other at 8 weeks of gestation. The two newborns required intensive care, one for respiratory distress syndrome and hypoglycaemia, and the other for increased bilirubin levels and moderate hypoglycaemia. No malformation occurred. The authors concluded that degludec was unlikely to be responsible for the neonatal adverse events since it was discontinued at least 5 months before birth [15] .
Additionally, a case of a pregnancy of a 31-year-old woman with type 2 diabetes who continued insulin degludec until delivery was described in 2018 [16] . Degludec administration was not associated with maternal complications or neonatal malformations.
Case 1 herein described is the first report in which insulin degludec was continued for the entire pregnancy duration in a woman with T1D. Maternal pregnancy complications were unlikely to be associated with insulin treatment. Also, neonatal complications were probably due to premature birth. In cases 2 and 3, no complication or adverse maternal or foetal event was observed in the first trimester and during the rest of gestation. Complete data of the six cases of pregnancy initiated during therapy with degludec so far available (three already published and three herein described) are summarized in Table 1 . Overall, these observations are consistent with no embryo toxicity of the drug. Notably, all cases occurred in Italy, where many T1D patients with glycaemic instability or a history of severe hypoglycaemia have been switched from glargine to degludec in view of the benefits reported by RCTs [17] . Since wide glycaemic excursions during pregnancy contribute to maternal and foetal complications, adverse events occurred during therapy with degludec in pregnancy cannot be univocally attributed to the drug itself versus the underlying patient's glycaemic profile (which may or may not be improved by degludec) or general attitude towards diabetes. Notwithstanding this possibility of reverse causality, the case series remain important to explore the safety of degludec in pregnancy, as they have been for other analogues in the past [6] , until results of a dedicated RCT become available.
3
In conclusion, owing to its stable pharmacokinetic profile and lower risk of hypoglycaemia, insulin degludec may in future become a valid option to optimize glycaemic control during pregnancy [14] . Data so far collected on six cases of degludec exposure during pregnancy suggest no embryo-foetal toxicity, but more information is needed before degludec can be safely recommended during pregnancy.
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